Multiple myeloma terminating in leukemia

Y. Manor, Z. Steiner, A. Klajman, A. Rozenszajn

Research output: Contribution to journalArticlepeer-review


Three patients suffering from multiple myeloma developed acute myelomonocytic leukemia. They exhibited IgG/k monoclonal gammopathy in their serum. They were treated with melphelan for a period of 33 to 65 months. From the diagnosis of multiple myeloma to the appearance of signs of acute myelomonocytic leukemia, 36, 48, and 68 months respectively, elapsed. The number of cases of multiple myeloma developing acute myelomonocytic leukemia has increased sharply of late. It is believed that this increase is due to treatment with melphelan. Another possibility is that this is the natural course of multiple myeloma in patients whose life has been prolonged by the treatment. The acute leukemia in these patients is refractory to treatment and is subacute in its manifestations. All three patients died and in one, death was hastened by the anti-leukemic treatment.

Original languageEnglish
Pages (from-to)117-119+155-156
Issue number3-4
StatePublished - 1978
Externally publishedYes


Dive into the research topics of 'Multiple myeloma terminating in leukemia'. Together they form a unique fingerprint.

Cite this